Company / Operating Cash Flow
ArriVent BioPharma, Inc. Operating Cash Flow History
FY2023-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$70.2M
FY2024
5-year range
-$70.2M / -$55.8M
FY2023-FY2024
Trend
-25.7%
vs FY2023
Sector context
#107 of 216
Health Care
What the data says
At -$70M, ArriVent BioPharma, Inc.'s operating cash flow ranks #107 of 216 in the Health Care sector.
Based on SEC 10-K filings.
-$70M in FY2024.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#107 of 216 in Health CareTop 50% of 216This company -$70.2M Sector average $658.7M
▼
-110.7% below sector average
Key checks
Key Insights
- In FY2024, operating cash flow decreased 25.7% year-over-year.
- Ranks #107 out of 216 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 5.74 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$70.2M | -25.7% |
| FY2023 | -$55.8M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026